Management of Crohn's Disease During Postpartum
Continue all Crohn's disease medications during the postpartum period except methotrexate, JAK inhibitors (tofacitinib, upadacitinib, filgotinib), and sphingosine-1-phosphate receptor modulators (ozanimod, etrasimod), as maintaining disease remission is critical for maternal health and most IBD therapies are safe during breastfeeding. 1
Medication Management During Breastfeeding
Safe to Continue While Breastfeeding
Biologics:
- Anti-TNF agents (infliximab, adalimumab, golimumab, certolizumab) are safe during breastfeeding, with minimal to no transfer into breast milk and no detectable levels in infant sera. 2, 1
- Anti-integrins (vedolizumab, natalizumab) may be continued while breastfeeding. 1
- Anti-IL-12/23 and anti-IL-23 agents (ustekinumab, risankizumab, mirikizumab, guselkumab) are compatible with breastfeeding. 1
- Biosimilars to existing biologics are safe during breastfeeding. 1
Conventional Therapies:
- 5-ASA preparations transfer into breast milk in minimal amounts and are safe to continue. 2
- Corticosteroids are found in low concentrations in breast milk and may be continued; there is no compelling evidence to discard breast milk or avoid feeding within 4 hours of ingestion. 2, 1
- Thiopurines (azathioprine, 6-mercaptopurine) are acceptable during breastfeeding, with studies showing no detectable metabolites in infant sera and age-appropriate development in exposed infants. 2
Medications to Avoid During Breastfeeding
- Methotrexate should be avoided during breastfeeding due to potential accumulation in neonatal tissues, despite low milk-to-plasma ratios. 2, 3
- JAK inhibitors (tofacitinib, upadacitinib, filgotinib) should not be used while breastfeeding due to insufficient safety data. 3, 1
- Sphingosine-1-phosphate receptor modulators (ozanimod, etrasimod) are contraindicated during breastfeeding. 1
Disease Monitoring and Flare Management
Active disease monitoring is essential postpartum, as this period carries increased risk for disease flares. 4
For postpartum disease flares:
- Optimize existing 5-ASA therapy (oral and rectal combination) for mild-to-moderate ulcerative colitis flares. 2
- Initiate systemic corticosteroids or anti-TNF therapy for flares on optimized 5-ASA or thiopurine maintenance. 2
- Start anti-TNF therapy for corticosteroid-resistant flares. 2
- Continue breastfeeding during flare management, as the decision to breastfeed should be made independent of therapy. 2
Infant Vaccination Considerations
Live vaccine administration depends on maternal medication exposure during pregnancy:
- Infants exposed to anti-TNF agents with transplacental transfer (infliximab, adalimumab, golimumab after gestational week 20; etanercept after gestational week 32) should delay BCG vaccination for 6 months due to risk of disseminated BCG infection. 2, 3
- Rotavirus vaccination can be administered on the usual schedule regardless of in utero TNF inhibitor exposure, as evidence shows no increased risk of adverse events. 3
- All non-live vaccines should be given according to standard schedules regardless of in utero medication exposure. 3, 1
- Infants exposed to JAK inhibitors or sphingosine-1-phosphate receptor modulators in utero may receive live vaccines after 1 month of age. 1
- Live vaccines can be given to infants of mothers breastfeeding while on biologics, as biologic transfer through breast milk is minimal. 1
Key Clinical Pitfalls to Avoid
Do not discontinue IBD medications postpartum to enable breastfeeding, as this significantly increases the risk of disease flare, which poses greater risk to both mother and infant than medication exposure through breast milk. 2, 5
Do not delay treatment of postpartum flares due to breastfeeding concerns, as uncontrolled disease activity has more detrimental effects on maternal health and infant care than medication exposure. 2, 4
Ensure clear communication about infant vaccination schedules based on specific maternal medication exposure during pregnancy, particularly regarding timing of live vaccines. 2, 3